KidneyIntelX.dkd
Progressive decline in kidney function in adults with Type 2 Diabetes and CKD Stages 1-3b
CommercialFDA Authorized, Medicare Covered
Key Facts
Indication
Progressive decline in kidney function in adults with Type 2 Diabetes and CKD Stages 1-3b
Phase
Commercial
Status
FDA Authorized, Medicare Covered
Company
About Renalytix
Renalytix plc is a global diagnostics company with a mission to improve kidney health through AI-enabled risk prediction. Its key achievement is the FDA authorization and subsequent Medicare coverage determination for its KidneyIntelX.dkd prognostic test for diabetic kidney disease. The company's strategy is to commercialize this test and expand its platform to other kidney conditions, leveraging partnerships to drive adoption and integrate its solutions into standard care pathways.
View full company profile